The latest price target for Corbus Pharmaceuticals (NASDAQ:CRBP) was reported by RBC Capital on August 28, 2024. The analyst firm set a price target for $82.00 expecting CRBP to rise to within 12 months (a possible 66.23% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Corbus Pharmaceuticals (NASDAQ:CRBP) was provided by RBC Capital, and Corbus Pharmaceuticals reiterated their outperform rating.

The last upgrade for Corbus Pharmaceuticals Holdings Inc happened on March 6, 2024 when Jefferies raised their price target to $46. Jefferies previously had a hold for Corbus Pharmaceuticals Holdings Inc.

There is no last downgrade for Corbus Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corbus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corbus Pharmaceuticals was filed on August 28, 2024 so you should expect the next rating to be made available sometime around August 28, 2025.

While ratings are subjective and will change, the latest Corbus Pharmaceuticals (CRBP) rating was a reiterated with a price target of $82.00 to $82.00. The current price Corbus Pharmaceuticals (CRBP) is trading at is $49.33, which is out of the analyst’s predicted range.